HomeCompareIPSEF vs QSR

IPSEF vs QSR: Dividend Comparison 2026

IPSEF yields 1.45% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPSEF wins by $16.5K in total portfolio value· pulled ahead in Year 4
10 years
IPSEF
IPSEF
● Live price
1.45%
Share price
$113.13
Annual div
$1.64
5Y div CAGR
38.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.2K
Annual income
$6,651.20
Full IPSEF calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — IPSEF vs QSR

📍 IPSEF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSEFQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSEF + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSEF pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSEF
Annual income on $10K today (after 15% tax)
$123.06/yr
After 10yr DRIP, annual income (after tax)
$5,653.52/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, IPSEF beats the other by $5,323.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSEF + QSR for your $10,000?

IPSEF: 50%QSR: 50%
100% QSR50/50100% IPSEF
Portfolio after 10yr
$32.9K
Annual income
$3,519.54/yr
Blended yield
10.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

IPSEF
No analyst data
Altman Z
3.8
Piotroski
7/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSEF buys
0
QSR buys
0
No recent congressional trades found for IPSEF or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSEFQSR
Forward yield1.45%3.40%
Annual dividend / share$1.64$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.6%-0.8%
Portfolio after 10y$41.2K$24.7K
Annual income after 10y$6,651.20$387.88
Total dividends collected$18.8K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock

Year-by-year: IPSEF vs QSR ($10,000, DRIP)

YearIPSEF PortfolioIPSEF Income/yrQSR PortfolioQSR Income/yrGap
1$10,901$200.65$11,038$337.57$137.00QSR
2$11,947$283.32$12,156$345.43$209.00QSR
3$13,186$402.22$13,359$352.69$173.00QSR
4← crossover$14,684$575.02$14,654$359.36+$30.00IPSEF
5$16,541$829.46$16,045$365.45+$496.00IPSEF
6$18,909$1,210.33$17,539$370.97+$1.4KIPSEF
7$22,025$1,792.24$19,143$375.96+$2.9KIPSEF
8$26,271$2,704.08$20,863$380.42+$5.4KIPSEF
9$32,288$4,177.89$22,708$384.39+$9.6KIPSEF
10$41,199$6,651.20$24,685$387.88+$16.5KIPSEF

IPSEF vs QSR: Complete Analysis 2026

IPSEFStock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Full IPSEF Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this IPSEF vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSEF vs SCHDIPSEF vs JEPIIPSEF vs OIPSEF vs KOIPSEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.